The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer

• Published in: Scientific reports 2022-05, Vol.12 (1), p.8244-7, Article 8244
• Main Authors: Catalano, Martina, Aprile, Giuseppe, Conca, Raffaele, Petrioli, Roberto, Ramello, Monica, Roviello, Giandomenico
• Format: Article
• Language: English
• Subjects: 631/57; 631/67; 631/92; Age; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Chemotherapy; Comorbidity; Deoxycytidine - analogs & derivatives; Gemcitabine; Humanities and Social Sciences; Humans; Medical prognosis; Metastases; Metastasis; multidisciplinary; Paclitaxel; Pancreatic cancer; Pancreatic Neoplasms - pathology; Patients; Risk factors; Science; Science (multidisciplinary); Statistical analysis; Survival; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-12214-4

Few studies have evaluated the impact of risk factors such as performance status (PS) and comorbidities on overall survival (OS) in patients with metastatic pancreatic cancer (mPC). We investigated the influence of comorbidity, PS and age on nab-paclitaxel and gemcitabine (NabGem) effectiveness profile in naive patients with mPC. 153 patients with mPC treated with NabGem upfront was divided in three groups (score 0 to 3) based on the absence or the presence of one or more risk factors among: age ≥ 70 years, PS 1 and comorbidities and the clinical outcomes was compared. Fifty-five patients were elderly (≥ 70 years), 80 patients have PS 1, whereas the other have PS 0. Patients with no risk factors (score 0) had an overall survival higher (20 months) than patients with one or two risk factors (score 1–2) (OS 11 months) and with three risk factors (score 3) (OS 8 months) ( p